SOURCE: IBC Life Sciences

April 08, 2005 08:38 ET

New Reality in Drug Delivery Points to Strategic Partnerships

Pharmaceutical and Biotechnology Professionals Collaborate on Market Opportunities

WESTBOROUGH, MA -- (MARKET WIRE) -- April 8, 2005 -- Growth by acquisition and corporate collaboration is changing the drug delivery market. New techniques and technologies are driving this market to new heights. According to Drug Delivery Technology® magazine, the US market for drug delivery is forecasted to achieve a value of $49.9 billion by 2007, an increase of 51.2 percent since 2002.

IBC's Drug Delivery World: Find Practical New Technologies and Collaborative Partners to Increase your Market Share provides a targeted educational platform to assess technology, foster strategic relationships, find more effective ways to extend product lifecycles, and optimize the pipeline through compound-enabling programs. The conference is set for May 16-18, 2005 at the Estancia La Jolla Hotel and Spa in La Jolla, California.

Presentations and panel discussions focus on advanced transdermal products, fast dissolve orally disintegrating tablet technologies, and building true alliances.

Conference attendees will:

--  Hear case studies from Eli Lilly and Company, Boehringer Ingelheim,
    and Purdue Pharma LP on effectively negotiating collaborations
    
--  Analyze the technology assessment process and learn how to introduce
    nanotechnology, oral delivery, gastroretention, and chronotherapy
    technologies earlier in product strategy
    
--  Build alliances through an innovative customized networking session
    that raises the bar in leveraging technology, infrastructure and product
    potential by pairing contacts that have similar goals and objectives
    
--  Reach an integrated audience that weaves business and technology
    sessions designed to tap into the latest developments in drug delivery
    
--  Explore new methods to help interpret the vast amounts of difficult-to-
    understand regulations for extending and protecting a patent
    
It is estimated that from 2003-2005, 25 blockbuster products with combined sales of $26 billion will have lost patent protection. Two separate pre-conference workshops will analyze patent protection and an out- licensing process.

About IBC Life Sciences

IBC Life Sciences is an independent organizer that is in business to provide an unbiased forum for the evaluation of current research, market trends, technological developments and applications. IBC Life Sciences is part of IBC USA Conferences, Inc., a division of T&F Informa plc (London: TFI). T&F Informa was created through the merger of Informa Group plc and Taylor & Francis Group plc in May 2004. The two companies are market leaders in providing specialist information to commercial and academic markets through conferences and trade events, as well as academic, scientific and professional books, journals and newsletters. IBC USA Conferences is headquartered in Westborough, Massachusetts.

To download the complete agenda, visit: http://www.ibclifesciences.com/drugdelivery.

Contact Information